High-dose ethambutol: its role in intermittent chemotherapy. A six-year study.
The outcome of 81 patients receiving supervised ambulatory treatment with twice-weekly isoniazid and ethambutol is reported. The patients were divided into 2 groups, one of which received its entire outpatient treatment with isoniazid and ethambutol, the other receiving isoniazid and ethambutol after initial treatment with isoniazid and streptomycin. In both groups, there was a 100 per cent favorable response at completion of therapy and no relapes detected among those patients followed after treatment. We compared our results with other studies of intermittent-supervised therapy and concluded that twice-weekly isoniazid and ethambutol given up to 18 months after an adequate phase of daily treatment is a highly effective and well-tolerated regimen.
D000328:Adult; D000553:Ambulatory Care; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D004338:Drug Combinations; D004977:Ethambutol; D007538:Isoniazid